Govt. Urgently Needs to Deploy “Auto Disable Syringes” to Limit HIV Epidemic: Rajiv Nath, AISNMA

admin
admin
· 3 min read
Rajiv Nath, AISNMA on Auto Disable Syringes"

Saddened to hear about 46 people getting infected with HIV due to reuse of a single syringe, Mr. Rajiv Nath, President, All India Syringes and Needles Manufacturers Association (AISNMA) feels this could be just a tip of an iceberg as the problem is spread across the country. If this menace is not stopped, India could be staring at an HIV / AIDS epidemic, Mr. Nath said questioning National AIDS Control organization (NACO)’s lax attitude towards injection safety and preventable measures in its strategy to fight HIV.

Mr. Rajiv Nath said, ‘UP’s healthcare is fragile. It needs urgent HSS and introduction of UIP including urgent deployment of Auto Disable syringes and needle stick prevention IV Cannula to immediately limit epidemic from spreading.’

“Is injection safety in public healthcare a key element in NACO’s strategy to fight HIV as is done in Africa?”, Mr. Nath asked. The answer obviously is no as it thinks spread of infection via public healthcare is not an issue and therefore India has no funding or monitoring policy dedicated to public healthcare system strengthening . Further, there is no tracking of infections or registry via public healthcare from reuse of syringes/needles or needle stick injuries.

“NACO is myopic in limiting problem of Syringe reuse to only drug users”, Mr Nath said. Every time such tragedies like current one in Unnao  or earlier in Modasa in Gujarat happens, it causes discussions and publication of a Guideline book and then forgotten. Bad habits can’t be changed by education alone if culturally engrained and therefore reliance has to be on technology. As a car alarm forces you to belt up so does Auto Disable (AD) Syringes ensure- no possibility of Reuse.

Quoting WHO, Mr. Nath said that “Every $ 1 spent on injection safety saves $ 14 in public healthcare. A recent Health Technology Assessment study released by DHR finds Reuse Prevention AD Syringes cost effective at 1.90 Rs. Why use disposables that get misused and reused to become carrier of infection without universal precautions?” As in immunization, AD syringes can be used universally for all therapeutic injections.

In this context, it is important to ask, what is India’s Road Map to switch to Auto Disable Syringes as per WHO advisory to achieve this by 2020? Uganda and Tanzania banned imports and use of Std Disposable syringes to fight HIV and to disallow access to Quacks and Private sector to Disposable Syringes. Why it is not being done in India?, Mr Nath implored further.

The Ministers in various states of Health and Family Welfare and DGHS asks us to stop making Disposable Syringes and switch to AD syringes. We are ready to do so, but India should first stop buying disposable syringes in a predictable planned phased manner and switch to AD syringes and then CDSCO/ Regulators need to enforce a ban/ restricted access.

With more than 40 thousands Quacks in Delhi alone one can imagine how quickly and fiercely the HIV epidemic is spreading. Reusing syringes constitutes one of their main unsafe practices.  Therefore 46 people infected with HIV in Unnao of Uttar Pradesh could as well be news of any part of Delhi and anywhere from rest of India.

“It is high time Govt. takes immediate cognizance of the serious issue and deploy Auto Disable Syringes to save India from Threat of HIV / AIDS epidemic. It is MUST for India to enforce Injection Safety on priority basis” concluded Mr Nath.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk